| Assessment Status |
Awaiting full HTA submission from Applicant |
| HTA ID |
25056 |
| Drug |
Inavolisib |
| Brand |
Itovebi® |
| Indication |
Inavolisib, in combination with palbociclib and fulvestrant, is indicated for the treatment of adult patients with PIK3CA-mutated, oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer, following recurrence on or within 12 months of completing adjuvant endocrine treatment. |
| Rapid review commissioned |
02/09/2025 |
| Rapid review completed |
06/10/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of inavolisib compared with the current standard of care. |
| Full HTA commissioned by the HSE |
29/10/2025 |
| Pre-submission consultation with Applicant |
11/12/2025 |
